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One hundred seventy-two cases of patients with squamous cell 
cancer of the vulva treated at the University of Michigan Medical 
Center from 1975 to 1988 are reported. The mean age was 66 
years with a range of 21 to 101 years. The distribution by stage 
included Stage I, 65; Stage II, 44; Stage III, 50; and Stage IV, 
13 patients. Groin node dissections performed on 145 patients 
showed negative nodes, 58%; unilateral positive nodes, 28%; and 
bilateral positive nodes, 14%. The distribution of patients with 
positive nodes was influenced by stage: Stage I, 14%; Stage II, 
23%; Stage III, 72%; Stage IV, 92%. The overall cumulative S- 
year survival was 71% and this was significantly influenced by 
stage of disease: Stage 1, 94%; Stage II, 91%; Stage III, 36%; 
Stage IV, 26%. Stages I/II and III/IV were combined for analysis. 
In Stages I/II, survival was significantly influenced by tumor 
grade while size, patient age, and lymph node status did not 
influence survival. In Stage III/IV, survival was significantly 
influenced by tumor size, node status, and number of positive 
nodes while grade, patient age, and tumor location did not in- 
fluence survival. Squamous cell cancer of the vulva is effectively 
treated with radical surgery but advanced-stage disease with 
regional metastases significantly alters survival. 0 1991 AEademic 
press, Inc. 
INTRODUCTION 
Carcinoma of the vulva tends to be slow growing and, 
since it is an exterior disease on the vulva, should be 
amenable to treatment. Early in this century the necessity 
for radical resection of this disease was established [1,2]. 
An earlier report from our institution demonstrated that 
when radical resection is undertaken, the prognosis for 
this malignancy can be favorable [3]. This report was 
undertaken to analyze and update our experience with 
squamous cell carcinoma of the vulva. 
’ To whom reprint requests should be addressed at Northeastern Ohio 
Universities College of Medicine, 400 Wabash Ave.-A.C.C., Akron, 
OH 44307. 
MATERIAL AND METHODS 
A review of the clinical records, pathology reports, and 
tumor conference notes for patients diagnosed with car- 
cinoma of the vulva for the time period 1975-1988 was 
undertaken. All pathology was reviewed at the Gyne- 
cologic Tumor Conference, where recommendations for 
therapy were made. The original hematoxylin and eosin 
pathology slides were reviewed for patients with super- 
ficial lesions. In general well-differentiated tumors had 
little nuclear pleomorphism, cytologic atypia was not pro- 
nounced, there was a more normal nuclear to cytoplasmic 
ratio, and keratin production was abundant. Poorly dif- 
ferentiated tumors had smaller cells, frequent mitosis, 
pronounced nuclear pleomorphism, and hyperchromatic 
nuclei, and keratin formation was absent. Moderately dif- 
ferentiated tumors were intermediate in characteristics. 
Information for the clinical presentation, medical history, 
height, weight, and treatment were recorded. At the time 
of diagnosis all patients were staged according to the 
International Federation of Gynecology and Obstetrics 
(FIGO) guidelines utilizing the T-N-M system. The new 
FIG0 guidelines were not applied in a retrospective fash- 
ion. Survival was plotted with the life table method de- 
scribed by Kaplan and Meier [4]. The difference in sur- 
vival for various parameters was tested for significance 
by the generalized Wilcoxon (Breslow) methods [5]. 
RESULTS 
During the time period 197.5-1988, 204 patients with 
carcinoma of the vulva were treated at the University of 
Michigan Medical Center. During this time period, 172 
(85%) patients with squamous cell carcinoma of the vulva 
were evaluated. The other cell types included adenocar- 
cinema (9), melanoma (8), Paget’s disease (7), sarcoma 
(5), and basal cell (3). The distribution by stage for pa- 
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tients with squamous cell cancer included Stage I, 65; 
Stage II, 44; Stage III, 50; and Stage IV, I3 patients. The 
mean age was 66 years with a range of 21 to 101 years. 
The mean age of the patients according to the stage of 
disease included Stage I, 60.6 years; Stage II, 68.2 years; 
Stage III, 71.5 years; and Stage IV, 64.2 years. The clin- 
ical characteristics included Caucasian race, 169/172 
(98%); obesity, 64/170 (38%); smoking, 44/166 (27%); 
diabetes, 21/134 (16%); and hypertension, 54/134 (40%). 
The malignancy was located on the right side in 49 pa- 
tients (30%), was on left side in 42 patients (26%), and 
was bilateral in 71 patients (44%). The location of the 
lesion included labium minus, 30 (18%); labium majus, 
49 (30%); perineum, 28 (17%); clitoris, 44 (27%); and 
entire vulva, 14 (8%). Some type of vulvectomy was per- 
formed on 169 patients. The following surgical approaches 
were used: en bloc butterfly, 94 (55%); three separate 
incisions, 42 (25%); radical vulvectomy only, 15 (9%) (5 
for palliation); and radical hemivulvectomy, 18 (11%). 
Nine patients (5%) who presented with advanced lesions 
had palliative therapy which included vulvectomy (six), 
radiation therapy (two), and pain management (one). 
Groin node dissection was performed on 145 patients 
and 84 (58%) had negative nodes, 41 (28%) had positive 
unilateral nodes, and 20 (14%) had bilateral groin nodes 
involved with metastatic disease. A unilateral groin node 
dissection was performed on 11 patients with Stage I or 
Stage II disease. The distribution of positive lymph nodes 
by stage included Stage I, 14% (all unilateral); Stage II, 
23% (all unilateral); Stage III, 72%; and Stage IV, 92%. 
Thirty-eight patients underwent pelvic node dissection. 
Twenty-five patients had negative pelvic lymph nodes and 
thirteen patients had positive pelvic lymph nodes. All 
patients with positive pelvic nodes had positive groin 
nodes. The distribution of positive pelvic nodes by stage 
included Stage I, O/4; Stage II, O/8; Stage III, 7/B 
(39%); and Stage IV, 6/8 (75%). 
All 172 patients were available for follow-up except for 
1 patient, who was lost to follow-up immediately after 
treatment. In this group of 171 patients, the 2-year cu- 
mulative survival was 75%, and the 5-year cumulative 
survival was 71%. The cumulative 5-year survival was 
significantly influenced by the stage of disease: Stage I, 
94%; Stage II, 91%; Stage III, 36%; Stage IV, 26% (Fig. 
1). There was no significant difference in the survival 
between Stages I and II. These two groups had a com- 
bined cumulative 5-year survival of 93%. There was no 
significant difference in survival between Stage III and 
IV disease. These two groups had a combined cumulative 
5-year survival of 33%. The differences in stage of disease 
overwhelmingly influenced survival and, for this reason, 
Stages I/II and Stages III/IV were combined for further 
analysis. 
In Stage I/II disease, all patients had negative surgical 
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FIG. 1. Survival for patients squamous cell cancer of the vulva by 
stage of disease. 
margins and the factors that did not significantly influence 
survival included the size of the tumor, the age of the 
patient, the lymph node status, the location of the tumor, 
and the type of surgery. Patients with a poorly differ- 
entiated tumor had a significantly worse survival than 
those with a well-differentiated or moderately differen- 
tiated tumor (Fig. 2). Twenty-nine patients with Stage I 
disease had a superficially invasive lesion to a depth of 2 
mm or less. Twenty-four patients had a depth of invasion 
less than 1 mm, and five patients had l- to 2-mm pene- 
tration. There were no deaths among these patients with 
superficial lesions. The following treatments were em- 
ployed for these superficial lesions without a vulvar re- 
currence: butterfly en bloc radical vulvectomy, 6; three 
separate incision radical vulvectomy, 5; radical vulvec- 
tomy, 6. The 11 patients who had groin node dissection 
all had negative lymph nodes. A hemivulvectomy, in a 
wide excisional fashion, was performed for the remaining 
12 patients. Two of these twelve patients developed a 
recurrence. One patient had 1 mm of invasion. Two years 
later she had 2 mm of invasion and a radical vulvectomy 
was performed. One patient had less than 1 mm of in- 
vasion and 6 years later underwent wide local excision 
for carcinoma in situ. 
Patients with Stage III/IV disease were then analyzed 
for factors related to survival. The grade of tumor, age 
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FIG. 2. Survival for patients with Stage I/II disease by tumor 
differentiation. 
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FIG. 3. Survival for patients with Stage III/IV disease by tumor 
location. 
of the patient, and tumor location (Fig. 3) did not sig- 
nificantly influence survival. Factors found to significantly 
influence survival included the size of the lesion (Fig. 4) 
the lymph node status (Fig. 5), and the pelvic lymph node 
status (Fig. 6). In Stage III/IV disease, the presence of 
unilateral positive groin nodes decreased survival to 30% 
while the presence of bilateral groin lymph nodes de- 
creased survival to 7%. The presence of positive pelvic 
nodes decreased survival to 8%. No patient with negative 
groin nodes had positive pelvic lymph nodes. The total 
number of positive lymph nodes significantly influenced 
survival (Fig. 7). 
Postoperative complications included 1 postoperative 
death from gram negative sepsis, which occurred in 1976. 
A total of 86 patients (50%) experienced some type of 
wound complication. These complications included 
wound infection, 28; wound cellulitis, 25; lymphocyst, 33; 
and groin wound breakdown, 82. Twenty-five patients 
(17%) developed lymphedema, but none of these patients 
experienced severe debilitating lymphedema. Ten pa- 
tients (7%) experienced a problem with chronic cellulitis, 
thought to be related to the groin lymph node dissection. 
Thirty-two patients were available for evaluation of re- 
current disease. Twenty patients had local/regional re- 
currence and twelve had distant metastases. All 12 pa- 
tients who developed distant metastatic disease had 
original Stage III/IV disease. 
DISCUSSION 
Squamous cell carcinoma of the vulva is a disease that 
tends to remain localized for extended periods of time. 
In this report there is a difference in mean age between 
Stage I and III of 11 years. This could be explained by 
a progression interval of approximately one decade from 
early to advanced disease. Alternatively it is possible that 
the elderly patient presents at a later date. The 2-year 
survival of 75% and the 5-year survival of 71% reported 
here attest to the fact that excellent survival can be ob- 
tained with the primary surgical approach. Thus surgery 
should remain the primary mode of therapy for this dis- 
ease and the present survival results are similar to the 
73.9% previously reported from our institution for the 
40-year time period 1935-1975 [3]. 
The most significant factor for predicting survival in 
this disease remains the stage of the disease. Patients 
diagnosed early, prior to the presence of clinically positive 
lymph nodes, have a prognosis significantly improved over 
that of patients with advanced-stage disease, which often 
involves regional lymph nodes. The stage of disease sig- 
nificantly influences survival, as has been confirmed by 
other authors. In the present study the survival is similar 
stage for stage to that previously reported by both our 
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FIG. 4. Survival for patients with Stage III/IV disease according 
to the tumor size. 
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FIG. 5. Survival for patients with Stage III/IV disease according 
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FIG. 6. Survival for patients with Stage III/IV disease according 
to the pelvic lymph node status. 
a decrease in survival to 50% for Stage III disease and 
to 0% for Stage IV disease [7]. Shimm et al., like us, 
reported that survival was significantly related to the stage 
of disease, the size of the tumor, and the lymph node 
status [8]. There has been a marked decrease in the num- 
ber of patients presenting with advanced lesions where 
only palliation is offered. In the previous time period, 63 
patients (21%) presented with disease amenable only to 
palliation while in this reported time span only 9/172 
(5%) from our institution were considered for palliation 
PI* 
As in other reports, our study found the presence of 
unilateral or bilateral node metastases and pelvic node 
involvement to be a significant predictor of survival [7- 
9]. Additionally the total number of involved nodes pre- 
dicts extremely high risk groups. Unlike advanced-stage 
disease, however, node metastases in Stage I/II do not 
carry an unfavorable prognosis. This was our experience 
in the years prior to 1975 and it is demonstrated in this 
report. Hoffman et al., in analyzing the microscopic fea- 
tures of involved lymph nodes, reported that small foci 
in nodes did not alter prognosis while nodes largely re- 
placed by tumor did decrease survival [lo]. The patients 
with Stage I/II disease had clinically nonsuspicious nodes 
consistent with microscopic disease while patients with 
Stages III/IV often had large palpable suspicious nodes. 
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PIG. 7. Survival for patients with Stage III/IV disease according to the number of positive lymph nodes. 
This report confirms that squamous cell carcinoma of 
the vulva has an overall favorable prognosis. The greatest 
challenge however remains earlier diagnosis prior to the 
presence of advanced local disease or metastatic spread 
to lymph nodes. 
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